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Abstract: BACKGROUND AIMS: The organic anion-transporting polypeptide 1B1 (OATP1B1) is
an anion exchanger expressed at the hepatocyte sinusoidal membrane, which mediates the uptake of
several endogenous metabolites and drugs. OATP1B1 expression level and activity are major sources
of inter-patient variability of pharmacokinetics and pharmacodynamics of several drugs. Besides the
genotype, factors that contribute to the inter-individual variability in OATP1B1 expression level are
practically unknown. The aim of this work was to uncover novel epigenetic mechanisms of OATP1B1
regulation. METHODS: A functional screening strategy to assess the effect of microRNAs on the uptake
of estrone-3-sulphate, an OATP1B1 substrate, into human hepatocellular carcinoma (Huh-7) cells was
used. microRNA-206 (miR-206) expression in human liver tissues was measured by real-time RT-PCR.
OATP1B1 expression in Huh-7 and in human liver tissues was assessed by real-time RT-PCR, Western
blotting and immunostaining. The mRNA-miRNA interaction was assessed by reporter assay. RESULTS:
miR-206 mimic repressed mRNA and protein expression of OATP1B1 in Huh-7 cells. The intracellular
accumulation of estrone-3-sulphate was reduced by 30% in cells overexpressing miR-206. The repressive
effect of miR-206 on the activity of the firefly luciferase gene 2 under the control of the OATP1B1 3’
untranslated region was lost upon deletion of the predicted miR-206 binding site. Hepatic miR-206
level negatively correlated with OATP1B1 mRNA and protein levels extracted from normal human liver
tissues. CONCLUSIONS: miR-206 exerts a suppressive effect on OATP1B1 expression by an epigenetic
mechanism. Individuals with high hepatic levels of miR-206 appear to display lower level of OATP1B1.
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Background & Aims: The organic anion transporting polypeptide 1B1 (OATP1B1) is 50 
an anion exchanger expressed at the hepatocyte sinusoidal membrane, which 51 
mediates the uptake of several endogenous metabolites and drugs. OATP1B1 52 
expression level and activity are major sources of inter-patient variability of 53 
pharmacokinetics and pharmacodynamics of several drugs. Besides the genotype, 54 
factors that contribute to the inter-individual variability in OATP1B1 expression level 55 
are practically unknown. The aim of this work was to uncover novel epigenetic 56 
mechanisms of OATP1B1 regulation. 57 
Methods: A functional screening strategy to assess the effect of microRNAs on the 58 
uptake of estrone-3-sulfate, an OATP1B1 substrate, into human hepatocellular 59 
carcinoma (Huh-7) cells was used. microRNA-206 (miR-206) expression in human 60 
liver tissues was measured by real time RT-PCR. OATP1B1 expression in Huh-7 and 61 
in human liver tissues was assessed by real time RT-PCR, western blotting and 62 
immunostaining. The mRNA-miRNA interaction was assessed by reporter assay.  63 
Results: miR-206 mimic repressed mRNA and protein expression of OATP1B1 in 64 
Huh-7 cells. The intracellular accumulation of estrone-3-sulfate was reduced by 30% 65 
in cells overexpressing miR-206. The repressive effect of miR-206 on the activity of 66 
the firefly luciferase gene 2 under the control of the OATP1B1 3’ untranslated region 67 
was lost upon deletion of the predicted miR-206 binding site. Hepatic miR-206 level 68 
negatively correlated with OATP1B1 mRNA and protein levels extracted from normal 69 
human liver tissues .  70 
Conclusions: miR-206 exerts a suppressive effect on OATP1B1 expression by an 71 
epigenetic mechanism. Individuals with high hepatic levels of miR-206 appears to 72 
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Lay Summary 77 
 The organic anion transporting polypeptide 1B1 (OATP1B1) is involved in the 78 
hepatic elimination of several endogenous metabolites and drugs.  79 
 Abnormal OATP1B1 expression levels can affect the pharmacological and 80 
toxicological profile of a number of widely prescribed drugs. 81 
 High intrahepatic levels of the small non-coding RNA, microRNA-206, repress 82 














The organic anion transporting polypeptides (OATPs, SLCO) are electroneutral 95 
exchangers that mediate the transport of a wide variety of endogenous substrates (e.g. 96 
thyroid hormones, bilirubin, bile acids) and are important in the disposition of several 97 
drugs and other xenobiotics. Up to now, 12 human OATPs have been identified 1,2, of 98 
which the liver-specific OATP1B1, encoded by the SLCO1B1 gene, is best 99 
characterized 3,4. Loss of function mutations of OATP1B1 (and OATP1B3) have been 100 
associated with the Rotor syndrome, a rare, benign disease presenting with conjugated 101 
and unconjugated hyperbilirubinemia 5-7. Knock-out mice for Slco1b2, the orthologue 102 
of the human SLCO1B1 and SLCO1B3 genes, displayed higher level of unconjugated 103 
bile acids in plasma, suggesting a key role in clearing the blood from unconjugated bile 104 
acids 8.  105 
Data from several pharmacogenetic studies highlight the role of OATP1B1 expression 106 
level and activity in the pharmacokinetic/pharmacodynamic inter-patient variability of a 107 
number of drugs. A genome-wide study on patients under treatment with the 108 
cholesterol-lowering drug simvastatin associated two single nucleotide polymorphisms 109 
(SNPs) in the SLCO1B1 gene with the risk of myopathy: the noncoding rs4363657 and 110 
the nonsynonymous rs4149056 (c.T521C, p.V174A), with the latter resulting in 111 
impaired protein trafficking and activity in vitro 9,10. Genetic variants of the SLCO1B1 112 
gene have been associated with a lower clearance of methotrexate and a lower 113 
incidence of methotrexate-related mucositis in a genome-wide study on children with 114 
acute lymphoblastic leukaemia (ALL) treated with high-dose methotrexate 11. This 115 
finding was replicated in a larger cohort of patients with ALL treated with different 116 
regimens of high-dose methotrexate 12. Similar results have been reported for other 117 
statins, the antihistamine fexofenadine and antiretroviral drugs 13-15. The extensive 118 
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genetic evidence for the dominant role of OATP1B1 in drug hepatic clearance and its 119 
large substrate specificity led the regulatory agencies to add OATP1B1 (and 120 
OATP1B3) as a target of in vitro drug-drug interaction prediction 16,17. 121 
The genetic variability in the SLCO1B1 gene can only explain part of the relatively high 122 
inter-individual variability of hepatic OATP1B1 protein expression 18. The role of non-123 
genetic factors (e.g. age and nuclear transcription factors) in the basal expression level 124 
of the OATP1B1 may be marginal 18. The hepatocyte nuclear factor 1 homeobox A 125 
(HNF1α) activates transcription of the SLCO1B1 gene through direct binding to the 126 
promoter region 19. The farnesoid X receptor (FXR, NR1H4), which is activated by bile 127 
acids, has also been shown to regulate transcription of the SLCO1B1 gene, and is 128 
likely to be relevant in cholestatic condition 20,21. Little is known about the role played 129 
by microRNAs in regulating OATP1B1 expression 22,23. We adopted a functional 130 
screening strategy that assessed the effect of microRNAs on the uptake of estrone-3-131 
sulfate (E3S), a prototypic OATP substrate, into Human hepatocellular carcinoma-132 
derived (Huh-7) cells. We found that microRNA-206 (miR-206), by binding to the 3’ 133 
untranslated region (3’ UTR) of the OATP1B1 mRNA, may contribute to the post-134 
transcriptional regulation of OATP1B1. miR-206 is a 22-nucleotide non-coding RNA 135 
located in an intergenic region of chromosome 6. miR-206 is considered a myomiR 136 
because it is mainly expressed in the skeletal muscle, yet it has also been recently 137 




Patients and Liver Tissues 142 
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All the procedures followed the ethical standards in accordance with the Helsinki 143 
declaration and with the local law for medical scientific research with human beings. 144 
The local medical ethics committee “Medisch Ethische Toetsings Commissie van het 145 
Amsterdam UMC, locatie AMC” approved the protocol for this study before the General 146 
Data Protection Regulation (GDPR) law came into force, waiving the need of inform 147 
consent because the study employed unused material collected from treatment-148 
purpose hepatectomies. Patients with chronic hepatitis, hepatocellular carcinoma and 149 
cholangiocarcinoma were excluded.  The analysis was performed on the surrounding 150 
normal tissue from patients who underwent partial hepatectomy and with normal serum 151 
alpha-fetoprotein. The tissue was defined normal when the following features were 152 
present: (i) normal distribution of portal tracts and central veins, (ii) normal architecture 153 
of liver cell plates without significant inflammation, cholestasis and/or fibrosis, and 154 
copper and iron levels. Steatosis was graded as either negative (0%), less than 5%, 5-155 
33%, 34%-66% and >66%. Inflammation was graded from one to three (mid, moderate, 156 
severe), for lobular, interface and portal inflammation. The normal tissue was also 157 
assessed for presence of ballooning, bilirubinostasis, siderosis, and copper 158 
accumulation. Fibrosis was graded as following: none (0), perisinusoidal or periportal 159 
(1), perisinusoidal and portal/periportal (2), bridging fibrosis <50% (3), bridging fibrosis 160 
> 50% (4) and cirrhosis (5). More information about patient characteristics is listed in 161 
table 1.  162 
 163 
Reagents 164 
[6,7-3H(N)]estrone-3-sulfate ([3H]E3S, specific activity 45.6 Ci/mmol) was purchased 165 
from PerkinElmer (Boston, MA). Non-labelled E3S was provided by Sigma-Aldrich (St. 166 
Louis, MO). Lipofectamine 2000, miRNA mimic 206 (#4464066, miR-206), negative 167 
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control (#4464058), the miR-206 (#000510) and the U6 snRNA (#001973) 168 
amplification assays were purchased from ThermoFischer Scientific (Waltham, MA). 169 
The polyclonal anti-OATP1B1 antibody raised in rabbit was previously generated in 170 
our laboratory29. The antibody was affinity purified against the peptide used for 171 
immunization using a standard protocol. Anti-pan-actin, anti-protein disulphide 172 
isomerase (PDI) and horseradish peroxidase-conjugated secondary antibodies were 173 
provided by ThermoFischer Scientific (Waltham, MA). Penicillin/streptomycin mixtures, 174 
RPMI1640 and DMEM culture media were purchased from ThermoFischer Scientific 175 
(Waltham, MA). Biowest fetal bovine serum (FBS) was provided by VWR (Dietikon, 176 
CH).  177 
 178 
Cell lines 179 
Human hepatocellular carcinoma-derived (Huh-7) cells and Chinese Hamster Ovary 180 
(CHO) cells were grown at 37 °C with 5% CO2 and 95% humidity, in RPMI1640 and 181 
DMEM medium, respectively. Both media were supplemented with 10% FBS, 100 U/ml 182 
penicillin and 100 µg/ml streptomycin. DMEM medium was enriched with 100 µg/ml L-183 
proline. CHO cells stably transfected with the open reading frame of OATP1B1 (1B1-184 
CHO) were maintained under the selective pressure of G418 Geneticin at the 185 
extracellular concentration of 400 µg/ml 30,31. 186 
 187 
In silico prediction 188 
The open access softwares MiRWalk 2.0 (http://zmf.umm.uni-189 
heidelberg.de/apps/zmf/mirwalk2/, University of Heidelberg; Germany), Targetscan 190 
7.0 (http://www.targetscan.org/vert_70/, Whitehead Institute for Biomedical Research, 191 
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Cambridge, MA) and DIANA tools (http://diana.imis.athena-192 
innovation.gr/DianaTools/index.php, University of Thessaly, Greece) were employed 193 
to identify possible binding sites of the mature miR-206 and the OATP1B1 mRNA.  194 
 195 
Cloning of the full-length and the truncated 3’ UTR of the OATP1B1 mRNA 196 
The sequence of the complete (605 bp) and the truncated (r.2762_2786del, 582 bp) 197 
3’-untranslated region (3’UTR) of the SLCO1B1 gene (Accession NG_011745) were 198 
amplified from 100 ng of Human Genomic DNA (ThermoFischer Scientific, Waltham, 199 
MA), blunt ligated in pGEM-T vector and then subcloned in pmirGLO. Primer 200 
sequences used for the cloning of the complete OATP1B1 3’UTR were: 5’ -201 
TCTAGAGGGGAGAAAAAAAGCCACTTCTG- 3’ (Fw) and 5’ -202 
GCTAGCTTGCAAATATTGGAATGTCTTTATTTCTTC– 3’ (Re). Primer sequences 203 
used for the cloning of the truncated OATP1B1 3’UTR were: 5’ -GCTAGCGGGGAG 204 
AAAAAAAGCCACTTCT- 3’ (Fw) and 5’ -TCTAGATCTTCCACAATACTTAAATGT 205 
ATT- 3’ (Re). XbaI and NheI were used to subclone into the pmirGLO reporter plasmid. 206 
The final constructs were digested and resolved on a 0.8% agarose gel. The inserts 207 
were then sequenced by Microsynth (Balgach, Switzerland).   208 
 209 
RNA extraction and real time reverse transcription RT-PCR 210 
Total RNA from cells or from frozen tissue samples was extracted using the TRIzol 211 
Reagent (Life Technologies, Carlsbad, Ca). mRNAs were reverse transcribed to cDNA 212 
using random hexamers as primers and MultiScribe Reverse Transcriptase (Life 213 
Technologies, Carlsbad, Ca). For miR-206 and U6 level assessment, 10 ng of total 214 
RNA were reversed transcribed according to the manufacturer’s instructions, using 215 
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specific primers commercially available. The cDNA products were used as template 216 
for PCR amplification by Taqman® assay analysis with the TaqMan Fast Advanced 217 
Master Mix (ThermoFischer Scientific, Waltham, MA) on ABI 7900HT (AB Applied 218 
Biosystems, Foster City, CA, USA). 219 
 220 
Immunofluorescence 221 
Huh-7 cells were seeded on chamber-slides at a density of 5x104 cells/well (LAB-TEK, 222 
Naperville, IL). Twenty-four hours later, cells were transfected with miR-206 mimic or 223 
negative control. Seventy-two hours post-transfection, cells were washed with cold 224 
PBS, fixed in 4% paraformaldehyde, and permeabilized for 15 min with 0.1% Triton X-225 
100 and 30 min with 0.1% Tween 20/1% BSA in PBS. Then, the cells were incubated 226 
at 4 °C overnight with the polyclonal anti-OATP1B1 antibody. After washing, the cells 227 
were stained with AlexaFluor 488 goat anti-rabbit IgG (ThermoFischer Scientific, 228 
Waltham, MA). Cells were mounted with DAPI (Vector Laboratories) and visualized 229 
under a confocal microscope. Immunostaining of OATP1B1 in WT-CHO and 1B1-CHO 230 
was performed following the same procedure, and served as negative and positive 231 
controls, respectively. 232 
 233 
Histological analysis 234 
For diagnostic assessment of liver tissue, the following standard staining protocols 235 
were used: Hematoxylin and eosin (HE), Periodic acid–Schiff (PAS), PAS stain in 236 
combination with diastase (PAS-D), reticulin (RET), sirius red, elastica van Gieson, 237 
copper, iron and Cytokeration 7 (CK7). Immunostaining of OATP1B1 was performed 238 
on paraffin sections using a microwave-based antigen-retrieval technique. Sections 239 
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were treated with the Envision+ DAB kit (Dako, Denmark) according to the 240 
manufacturer’s instruction then probed with the anti-OATP1B1. Two unbiased 241 
observer assessed the OATP1B1 expression level according to the H scoring system 242 
32. Three high-power fields were analysed per sample. 243 
 244 
Protein sample preparation for Western blotting 245 
Western blotting from liver samples was performed using total membrane fractions 246 
isolated from human liver tissues or Huh-7 cells as previously described 33. For tissue 247 
total membrane preparation, at least 100 mg of frozen tissue were homogenized with 248 
a Polytron in 300 mM sucrose buffer supplemented with a protease inhibitor cocktail 249 
(Roche Diagnostics, Indianapolis, IN). For Huh-7 cells total membrane preparation, 250 
cells were transfected with miR-206 mimic or negative control and 72h post-251 
transfection homogenized with a Polytron in 250 mM sucrose buffer supplemented with 252 
protease inhibitor cocktail. Tissue and cell homogenates were spun down at 1300gav 253 
in a Sorvall SS34 rotor for 10 minutes. The supernatant was further centrifuged for 1 254 
hour at 100000gav in a Kontron Ultracentrifuge. The pellets containing the liver or the 255 
Huh-7 cells total membrane fractions were resuspended in 300 and 250 mM sucrose 256 
respectively, aliquoted and stored until use at – 80 °C.  257 
 258 
Western blotting 259 
One to two hundred µg of protein samples were resolved on a 8% (w/v) polyacrylamide 260 
gel and electroblotted onto nitrocellulose membranes (GE HealthCare, Piscataway, 261 
NJ). The membranes were blocked with 5% nonfat dry milk in PBS supplemented with 262 
0.1% (v/v) Tween 20 (PBS-T) and incubated overnight at 4°C with anti-OATP1B1 263 
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antibody, followed by probing with horseradish peroxidase-conjugated anti-rabbit IgG 264 
antibody. Blots were developed with SuperSignal West Femto Maximum Sensitivity 265 
Substrate (Thermo Scientific, Waltham, MA). The images were acquired and analysed 266 
with the Fusion FX7 (Vilber Lourmat, Eberhardzell, Germany). As a loading control, 267 
the sample blots were stripped and reprobed with anti-actin or anti-PDI followed by 268 
horseradish peroxidase-conjugated anti-mouse IgG antibody.  269 
 270 
Transport assay 271 
Huh-7 cells were seeded on a 96-well plate at a density of 4x104 cells/well. Twenty-272 
four hours later, cells were transfected with miR-206 mimic or negative control and 273 
grown for 72 hours. Uptake of estrone-3-sulfate (E3S) was measured as follows: cells 274 
were washed in transport buffer (136 mM NaCl, 5.3 mM KCl, 1.1 mM KH2PO4, 1.8 mM 275 
CaCl2, 0.8 mM MgSO4, 11 mM D-glucose and 10 mM Hepes/Tris, pH 7.4) at 37°C, 276 
then incubated for 10 minutes with pre-warmed transport buffer containing E3S at the 277 
extracellular concentration of 1 µM, spiked with [3H]E3S. The plate was rapidly 278 
transferred on ice and extensively washed with ice-cold transport buffer. Cells were 279 
solubilized in 0.1 mL of 1% (w/v) Triton X-100. Seventy-five l of the lysate was mixed 280 
with 3 ml of Scintillation Liquid (Ultima Gold, PerkinElmer, Switzerland) and assessed 281 
for intracellular radioactivity by liquid scintillation counting. Protein content was 282 
determined by the bicinchoninic acid protein assay on the remaining 25 l (Interchim, 283 
Montluçon Cedex, France). 284 
 285 
Luciferase assay 286 
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The direct binding of miR-206 to the OATP1B1 3′UTR was assessed by sub-cloning 287 
the full or the truncated (r.2762_2786del) OATP1B1 3′UTR into the pmirGLO Dual-288 
Luciferase miRNA Target Expression Vector (Promega, Madison, WI) downstream of 289 
the coding sequences of the firefly luciferase 2 (luc2) gene. Huh-7 cells were seeded 290 
in 48-well plates at a density of 4×104 cells/well. After 24h, the cells were transfected 291 
with 100 ng/well of pmirGLO plasmid containing the full or the truncated OATP1B1 292 
3′UTR. The empty pmirGLO plasmid was used as a control. Afterwards, cells were 293 
transfected with 0.25 µM miR-206 mimic or the same concentration of an unrelated 294 
microRNA used as a negative control. Twenty-four hours later the cells were processed 295 
using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according 296 
to the manufacturer's protocol. The luminescent signals were measured with the 297 
GloMax Multi Detection System (Promega, Madison, WI). 298 
 299 
Statistical Analysis 300 
Statistical comparisons were performed from at least three independent 301 
measurements, with the two-tailed Student's t-test. The correlation between OATP1B1 302 
expression and miR-206 levels was assessed by Pearson’s and Spearman's Rank-303 
Order correlation. All statistical analyses were performed using GraphPad Prism 304 




Effect of miR-206 on OATP1B1 expression level 309 
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Figure 1 shows that the transient transfection of Huh-7 cells with the miR-206 mimic at 310 
extracellular concentrations ≥ of 0.25 µM resulted in a 70% reduction of OATP1B1 311 
mRNA level in comparison with that in cells transfected with an unrelated microRNA 312 
used as a negative control. To test the impact of miR-206 on the protein level of 313 
OATP1B1, Western blotting and immunostaining of OATP1B1 was performed on Huh-314 
7 cells 72h after transfection with the miR-206 mimic or the negative control, at an 315 
extracellular concentration of 0.25 µM. The antibody specificity was confirmed on CHO 316 
cells stably transfected with OATP1B1 and the respective wild-type, which does not 317 
express OATP1B1. Figure 1B shows that OATP1B1 localizes predominantly at the 318 
plasma membrane of Huh-7 cells and a weaker staining intensity was observed in cells 319 
overexpressing miR-206 as compared with the mock transfected cells (Fig. 1B, bottom 320 
panels). Figure 1C shows that OATP1B1 was detected at two different molecular 321 
weights (70 kDa and 100 kDa) in 1B1-CHO cells, which are consistent with two 322 
different glycosylation patterns34. In Huh-7 cells, OATP1B1 appears to be expressed 323 
primarily at lower molecular weight (70 kDa) and its expression was reduced by ~ 50% 324 
(P=0.01) after transfection with miR-206 mimic (Fig. 1D).  325 
 326 
Effect of miR-206 on the intracellular accumulation of estrone-3-sulfate 327 
Estrone-3-sulfate requires a facilitative transport system to enter cells and represents 328 
a prototypic substrate of the OATPs. Indeed the uptake of E3S was temperature-329 
dependent and saturated upon co-incubation with an excess of non-labeled E3S, 330 
indicating that the uptake of E3S in Huh-7 cells was carrier mediated (Fig. 2A). Huh-7 331 
cells transiently transfected with miR-206 displayed a ~30% lower intracellular level of 332 
E3S as compared with the control transfected cells (P=0.003), compatible with a 333 




Impact of the r.2762_2786del in the OATP1B1 mRNA on miR-206-mediated 336 
repression of OATP1B1 expression level 337 
miR-206 was predicted, by the MiRWalk 2.0 and the Targetscan 7.0 softwares, to bind 338 
to the mRNA of the SLCO1B1 gene in the 3’ UTR in close proximity to the polyA tail (r. 339 
2771_2778). To assess the direct binding of the miR-206 to the OATP1B1 mRNA, the 340 
3’ UTR of the OATP1B1 mRNA containing the predicted binding site for the miR-206 341 
and a truncated version with a deletion of the last 25 bases were cloned into the 342 
pmirGLO vector. The activity of the firefly luciferase was monitored after transient 343 
transfection with the miR-206 mimic or an unrelated microRNA as a negative control. 344 
In figure 3A it can be seen that the reporter activity was reduced by ~ 60% by the miR-345 
206 mimic as compared with the negative control (P=0.003). The effect of miR-206 on 346 
reporter activity was abolished by the r.2762_2786 deletion (P=NS) (Fig. 3B), 347 
suggesting that the repressive effect of miR-206 on the OATP1B1 mRNA and protein 348 
level was the result of direct binding of miR-206 to the 3’ UTR of the OATP1B1 mRNA. 349 
 350 
OATP1B1 and miR-206 expression level in human liver 351 
The relative expression levels of OATP1B1 and miR-206 were assessed from the 352 
normal liver tissue of twenty patients who underwent partial hepatectomy. All the 353 
tissues included in the analysis showed normal distribution of portal tracts and central 354 
veins, and normal architecture of liver cells with minor or no signs of inflammation, 355 
fibrosis, and copper and iron levels. Seven out of 20 patients were diagnosed with 356 
steatosis (table 1). Figure 4 shows that the levels of OATP1B1 mRNA (Fig. 4A) and 357 
miR-206 (Fig. 4B) varied substantially among the samples. Notably, individuals with 358 
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high miR-206 levels exhibited low levels of OATP1B1 mRNA. Conversely, high mRNA 359 
levels of OATP1B1 were associated with low levels of miR-206. A relatively strong 360 
negative correlation was found between OATP1B1 mRNA and miR-206 levels (Fig. 361 
4C). The inset in figure 4C describes the level of OATP1B1 mRNA as a function of that 362 
of miR-206 when the three patients with the highest miR-206 value were excluded from 363 
the analysis. There was no difference in the OATP1B1 mRNA levels between steatotic 364 
and non-steatotic livers (Fig. 4D). Interestingly, the patients with the highest miR-206 365 
levels clustered in the non-steatotic group (Fig. 4E). This is in line with the reported 366 
protective role of miR-206 in liver steatosis in animals 25,28.  367 
Figure 5A shows representative high- and a low-intensity immunostaining for 368 
OATP1B1. Upon relative quantification of 16 out of 20 samples, based on the median 369 
value, a low and a high expression groups were defined. It can be seen that patients 370 
with the highest miR-206 level clustered together in the low OATP1B1 expression 371 
group (Fig. 5A, right panel). For 14 out of 20 samples, enough material was available 372 
to assess the protein level of OATP1B1 also by western blotting (Fig. 5B). There was 373 
a positive correlation between the mRNA and the protein levels of OATP1B1 (Fig. 5C), 374 
and a negative correlation between miR-206 level and the OATP1B1 protein level (Fig. 375 




miR-206 directly interacts with the OATP1B1 mRNA at the level of the 3’UTR, and 380 
reduces the mRNA and protein levels, presumably as a consequence of enhanced 381 
degradation of the OATP1B1 transcript and/or repression of protein synthesis 35,36. 382 
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While the reduction of the OATP1B1 mRNA level by the miR-206 mimic was already 383 
achieved at the lowest extracellular concentrations of miR-206 mimic tested (0.05-0.1 384 
M), the effect was best reproduced at an extracellular concentration of 0.25 M or 385 
more, due perhaps to variability in transfection efficiency. The transient transfection of 386 
miRNA mimic at such relatively high concentrations carries the risk of altering gene 387 
expression in a non-specific manner 37. Nevertheless, the effect of the miR-206 mimic 388 
on the OATP1B1 expression level in the Huh-7 cells appears to be specific: (i) the 389 
transient transfection with the same concentration of an unrelated miRNA mimic 390 
(negative control) did not repress OATP1B1 expression; (ii) the miR-206 mimic did not 391 
interact with the OATP1B1 3’UTR lacking the miR-206 predicted binding site. This is 392 
in line with the observation that most of the transfected miRNA mimic may be retained 393 
within vesicles and not accessible for loading into Argonaut as functionally active 394 
miRNA 38.  395 
The effect of miR-206 on OATP1B1 expression level in vitro was supported by the 396 
subsequent observation that individuals expressing high hepatic levels of miR-206 397 
displayed relatively low levels of OATP1B1. There was a negative correlation between 398 
the intrahepatic level of miR-206 and both OATP1B1 mRNA and protein levels. In line 399 
with a previous report, there was a positive correlation between mRNA and protein 400 
level of OATP1B118. Taken together, the data suggest that, especially when expressed 401 
at higher levels, miR-206 may affect OATP1B1 expression in vivo. Noteworthy, miR-402 
206 may also contribute to the previously reported FXR-mediated indirect repression 403 
of OATP1B1 expression 20. It has been shown that the nuclear receptor SHP (NROB2), 404 
a genuine target of FXR, induces miR-206 expression 39. 405 
miR-206 seems to play a key role in the regulation of whole body glucose homeostasis 406 
in animals fed a high-fat diet by modulating the expression of glucose-6-phosphate 407 
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dehydrogenase, glucokinase and glucose transporters in the intestine and pancreatic 408 
islets but not in the liver 40. Liver-specific overexpression of miR-206 has been shown 409 
recently to protect against steatosis by inhibiting the Sterol Regulatory Element Binding 410 
Protein 1c (Srebp1c) and the Liver X receptor alpha (LXRalpha) transcriptional activity 411 
and by facilitating insulin signalling via insulin receptor phosphorylation 25,28. 412 
Additionally, the level of miR-206 in hepatocellular carcinoma has been found to be 413 
lower than that in the normal liver, and miR-206 mimic injection was able to suppress 414 
carcinogenesis in two different mouse models of hepatocellular carcinoma 27. The 415 
present work consolidates the potential role of miR-206 in liver physiology. miR-206 416 
mainly originates from skeletal muscle and brown adipose tissue 24,26. While it cannot 417 
be excluded that the miR-206 measured in the present study was synthesized 418 
intrahepatically by resident cells (e.g. hepatocytes), it is possible that circulating miR-419 
206 may have entered and accumulated in the liver to regulate hepatocyte function. It 420 
was shown, first in plants and then in animals, that microRNAs synthesized in a distant 421 
tissue can be delivered systemically, retaining their activity and regulating the 422 
expression pattern of the target cell type 41,42.   423 
Although the repressive effect of miR-206 mimic transfection on OATP1B1 mRNA was 424 
pronounced, the reduction in transport activity was only moderate, albeit significant. 425 
This is not surprising since estrone-3-sulfate, like most OATP1B1 substrates, is also 426 
transported by other organic anion transporters, which may not be affected by the 427 
transfection with the miR-206 mimic1. Likewise, it cannot be ruled out that the reduced 428 
uptake of E3S in Huh-7 cells overexpressing miR-206 stems from the repression of 429 
some endogenous transporters, besides OATP1B1, that may contribute to the uptake 430 
of E3S in these cells. Nonetheless, because OATP1B1 is critical for the rate of 431 
elimination of several endogenous compounds and drugs, it is conceivable that the 432 
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effect of miR-206 levels on the pharmacokinetics of OATP1B1 substrates could be 433 
larger than that observed in Huh-7 cells 11,13-15,43. 434 
miRNAs are appealing as a class of therapeutics: rather than intercepting a single 435 
target as is the case of selective protein inhibitors, miRNAs would modulate entire gene 436 
cascades. miR-206 is a promising drug target: its use is under preclinical development 437 
in muscle-related diseases such as Duchenne muscular dystrophy and in a number of 438 
cancers including rhabdomyosarcoma 44,45. Our data suggest that the clinical 439 
development of miR-206 mimic for injection or of drugs that induces the endogenous 440 
miR-206 expression should include extensive drug-drug interaction studies, as miR-441 
206 may confer alterations in the pharmacokinetics and pharmacodynamics of 442 
OATP1B1 substrates by repressing OATP1B1 expression and, in turn, activity.  443 
To conclude, high hepatic levels of miR-206 may repress the expression of OATP1B1 444 
and may explain, at least part of the still unexplained inter-individual variability in 445 
OATP1B1 expression and, in turn, of the variable pharmacokinetics and toxicokinetics 446 
of many OATP1B1 substrates. Studies on larger cohorts of patients are necessary to 447 
establish whether the circulating miR-206 represents a candidate marker to identify 448 
patients with lower hepatic clearance of OATP1B1 substrates such as statins and 449 
methotrexate.   450 
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Table 1. Patient clinical characteristics. 595 
Parameters Category N (%)  

































































Other diagnoses: one patient with chronic cholestasis secondary to bile duct injury, 597 
one patient with liver metastasis of colon carcinoma and one patient with B-cell 598 
lymphoma. For steatosis grading: <5% (0), 5-33% (1), 34%-66% (2) and >66% (3). For 599 
inflammation grading: none (0), little (1), moderate (2) and severe (3). For fibrosis 600 
grading: none (0), perisinusoidal or periportal (1), perisinusoidal and portal/periportal 601 
(2), bridging fibrosis <50% (3), bridging fibrosis > 50% (4) and cirrhosis (5). 602 
 603 
  604 
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FIGURE LEGENDS 605 
Figure 1. OATP1B1 expression level in Huh-7 cells overexpressing miR-206. The 606 
mRNA and protein level of OATP1B1 in Huh-7 cells were assessed 48h and 72h after 607 
transient transfection with miR-206 mimic or the negative control, respectively. 608 
Ubiquitin C (UBC) gene and protein disulphide isomerase (PDI) were used as an 609 
internal control for mRNA quantification and immunoblotting. mRNA data are 610 
expressed relative to that in the control and are the mean  S.D. of 3 independent 611 
experiments (A). CHO cells stably transfected with OATP1B1 were used as a western 612 
blotting and immunostaining control. Western blotting and Immunofluorescence 613 
images (bar=50 µm) are representative of four independent experiments (B, C). 614 
OATP1B1 bands were quantified and expressed relative to the PDI band intensity (D). 615 
Figure 2. Uptake of estrone-3-sulfate in Huh-7 cells. Ten minutes uptake of estrone-616 
3-sulfate at an extracellular concentration of 1 M in non-transfected cells under the 617 
indicated conditions (A) and in cells after 72h transfection with miR-206 mimic or a 618 
negative control (B). Data are expressed as the mean  S.D. of four independent 619 
experiments.  620 
Figure 3. OATP1B1 3’UTR activity. Huh-7 cells were co-transfected with the miR-206 621 
mimic or the negative control and the pmirGLO-1B1 3’UTR (A) or the pmirGLO-1B1 622 
3’UTR_r.2762_2786del (B) constructs. Renilla reporter activity was used as an internal 623 
control. Values were normalized for those in the empty-vector transfected cells and are 624 
expressed relative to that in the control. Data are the mean  S.D. of four independent 625 
experiments. 626 
Figure 4. OATP1B1 mRNA and miR-206 levels in human liver samples. OATP1B1 627 
values are normalized to that of the Ubiquitin C (UBC) (A, C). miR-206 values are 628 
28 
 
normalized to those of the short RNA U6 (B, D). OATP1B1 mRNA level as a function 629 
of the miR-206 level (C). The inset shows OATP1B1 mRNA levels as a function of the 630 
miR-206 level upon exclusion of miR-206 value outliers. Data were correlated by 631 
Pearson’s and Spearman's Rank-Order analysis. OATP1B1 mRNA (D) and miR-206 632 
(E) levels in the steatosis subgroup. 633 
Figure 5. OATP1B1 protein level in human liver samples. Representative 634 
OATP1B1 immunohistochemistry of a high and low expressing tissue, and staining 635 
intensity quantification. Low expression and high expression samples were clustered 636 
based on the calculated median value (A). Western blotting of OATP1B1 from liver 637 
total membrane fraction. Pan-actin was used as a loading control (B). OATP1B1 mRNA 638 
level as a function of the OATP1B1 protein level (C). OATP1B1 protein level as a 639 
function of miR-206 level (D). Data were correlated by Pearson’s and Spearman's 640 
Rank-Order analysis. 641 
 642 
 643 
